Sumatriptan / Naproxen

What it is and how it works

Sumatriptan constricts cranial blood vessels and inhibits release of pro-inflammatory neuropeptides from trigeminal nerve endings via 5-HT1B/1D receptors. Naproxen inhibits cyclo-oxygenase and prostaglandin synthesis, reducing neurogenic inflammation; the combination targets different mechanisms of migraine.

Indications

Acute treatment of migraine attacks with or without aura in adults.

Dosage and administration (summary)

Oral: one tablet (sumatriptan 85 mg/naproxen 500 mg) at the onset of the attack; a second tablet may be taken after at least 2 hours if migraine recurs, maximum two tablets in 24 hours.

Contraindications

Ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension, severe hepatic or renal impairment, active peptic ulcer or GI bleeding, and use with ergotamine or MAOIs; recent CABG surgery.

Warnings and precautions

Triptans may cause coronary vasospasm; NSAIDs increase cardiovascular thrombotic and gastrointestinal bleeding risks. Serotonin syndrome may occur with SSRIs or SNRIs. Overuse may cause medication-overuse headache.

Pregnancy

Avoid, particularly in the third trimester when naproxen is contraindicated.

Storage and supply

Store below 25 °C.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.